This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients
with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55
patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the
the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib
500-750mg qd until progression of disease.